The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved July 1997

Specific Treatments:

chronic occlusive arterial disease

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Pentoxifylline is a 400 mg extended release tablet and the generic equivalent of Trental. It is being marketed by Hoechst Marion Roussel. Pentoxifylline extended release tablets are indicated for the treatment of leg pain caused chronic occlusive arterial disease of the limbs. Patient walking distance and daily activities are limited by the disease. Both Faulding and Mylan are now manufacturing Pentoxifylline.

Clinical Results

In a comparison between aspirin and pentoxifylline in the elderly, the level of pain did not change significantly with either aspirin or pentoxifylline, but patient’s walking distance was extended with the pentoxifylline group.

Mechanism of Action

Pentoxifylline increases red blood cell flexibility and improves blood flow.